Cancer: RNA-based approaches target KRAS

Comment

Sarah Crunkhorn. Nat Rev Drug Discov. 2017.

. 2017 Jul 31;16(8):529.

doi: 10.1038/nrd.2017.137.

No abstract available

Comment on

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Kamerkar S, et al. Nature. 2017 Jun 22;546(7659):498-503. doi: 10.1038/nature22341. Epub 2017 Jun 7. Nature. 2017. PMID: 28607485 Free PMC article.
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR. Ross SJ, et al. Sci Transl Med. 2017 Jun 14;9(394):eaal5253. doi: 10.1126/scitranslmed.aal5253. Sci Transl Med. 2017. PMID: 28615361